Source:http://linkedlifedata.com/resource/pubmed/id/21135860
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0009647,
umls-concept:C0013018,
umls-concept:C0017262,
umls-concept:C0023467,
umls-concept:C0026986,
umls-concept:C0030705,
umls-concept:C0035020,
umls-concept:C0150369,
umls-concept:C0185117,
umls-concept:C0206153,
umls-concept:C0265219,
umls-concept:C0333678,
umls-concept:C0681842,
umls-concept:C0694898,
umls-concept:C1332710,
umls-concept:C1879299,
umls-concept:C2323499,
umls-concept:C2698684,
umls-concept:C2911684
|
| pubmed:issue |
3
|
| pubmed:dateCreated |
2011-3-9
|
| pubmed:abstractText |
Relapse of malignant disease remains the major complication in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after hematopoietic cell transplantation (HCT) with reduced-intensity conditioning (RIC). In this study, we investigated the predictive value of disease-specific markers (DSMs), donor chimerism (DC) analysis of unsorted (UDC) or CD34(+) sorted cells and Wilms' tumor gene 1 (WT1) expression. Eighty-eight patients with AML or MDS were monitored after allogenic HCT following 2?Gy total-body irradiation with (n=84) or without (n=4) fludarabine 3 × 30?mg/m(2), followed by cyclosporin A and mycophenolate mofetil. DSMs were determined by fluorescence in situ hybridization (FISH) and WT1 expression by real-time polymerase chain reaction. Chimerism analysis was performed on unsorted or CD34(+) sorted cells, by FISH or short tandem repeat polymerase chain reaction. Twenty-one (24%) patients relapsed within 4 months after HCT. UDC, CD34(+) DC and WT1 expression were each significant predictors of relapse with sensitivities ranging from 53 to 79% and specificities of 82-91%. Relapse within 28 days was excluded almost entirely on the basis of WT1 expression combined with CD34(+) DC kinetics. Monitoring of WT1 expression and CD34(+) DC predict relapse of AML and MDS after RIC-HCT.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1476-5551
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
25
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
498-505
|
| pubmed:dateRevised |
2011-6-22
|
| pubmed:meshHeading |
pubmed-meshheading:21135860-Adult,
pubmed-meshheading:21135860-Aged,
pubmed-meshheading:21135860-Antigens, CD34,
pubmed-meshheading:21135860-Blood Donors,
pubmed-meshheading:21135860-Disease-Free Survival,
pubmed-meshheading:21135860-Female,
pubmed-meshheading:21135860-Genes, Wilms Tumor,
pubmed-meshheading:21135860-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:21135860-Humans,
pubmed-meshheading:21135860-In Situ Hybridization, Fluorescence,
pubmed-meshheading:21135860-Leukemia, Myeloid, Acute,
pubmed-meshheading:21135860-Male,
pubmed-meshheading:21135860-Middle Aged,
pubmed-meshheading:21135860-Myelodysplastic Syndromes,
pubmed-meshheading:21135860-Recurrence,
pubmed-meshheading:21135860-Transplantation Chimera,
pubmed-meshheading:21135860-Transplantation Conditioning
|
| pubmed:year |
2011
|
| pubmed:articleTitle |
Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.
|
| pubmed:affiliation |
Department of Hematology, Oncology and Hemostaseology, University of Leipzig, Leipzig, Germany. langet@medizin.uni-leipzig.de
|
| pubmed:publicationType |
Journal Article
|